rna-interference
(2)
Alicia Secor
After three decades turning complex science into operating companies, Alicia Secor has taken on a new translation problem: helping Paratus turn lessons from evolution into a disciplined pipeline of medicines.
Joanne Kotz
Joanne Kotz is a chemist-turned-biotech-CEO who runs Atalanta Therapeutics, a Boston company using divalent siRNA to silence disease-causing genes throughout the brain and spinal cord. She took the top job in June 2025 after co-founding and leading Jnana Therapeutics from a blank slate to a roughly $1 billion acquisition by Otsuka. Before founding companies she helped build them from the science up, as a director at the Broad Institute, a leader of F-Prime's neurodegeneration initiative, and the founding editor of Nature Chemical Biology. Her career runs an unusual loop: bench scientist, science journal editor, partnership architect, founder, and now CEO of a company chasing some of the hardest diseases in the central nervous system.